We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $1.74 · 6 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Mereo BioPharma : to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026 - marketscreener.com
Mereo BioPharma : to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026 marketscreener.com
MREO Stock Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
MREO Stock Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) ChartMill
Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026 - marketscreener.com
Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026 marketscreener.com
EcoR1, Oleg Nodelman report 8.4% stake in Mereo (MREO) - Stock Titan
EcoR1, Oleg Nodelman report 8.4% stake in Mereo (MREO) Stock Titan
Mereo BioPharma shareholders approve all resolutions at annual meeting - Investing.com
Mereo BioPharma shareholders approve all resolutions at annual meeting Investing.com
Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers - Stock Titan
Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.01 | — | — | $863.83K | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.02 | — | — | $0 | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.03 | — | — | $0 | Reported |
| FY2024 Q3 | 2023. 09. 30. | Time TBD | — | $-0.03 | — | — | $9M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 23. | JP Morgan | — | Downgrade | Overweight → Neutral | — | JP Morgan: Overweight → Neutral |
| 2026. 01. 17. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 01. 13. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2025. 12. 30. | Jefferies | — | Downgrade | Buy → Hold | — | Jefferies: Buy → Hold |
| 2025. 12. 30. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 525,125 | $218.82M | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 187,839 | $61.99M | 0.00% | — | New position |